Treasury Draft Rules Target Chinese Biotech Investments Amid Industry Pushback

Key points

• The Treasury Department published draft regulations on October 22, 2026, to curb US investment in Chinese biotechnology, AI, and hypersonic weapons.
• The rules prohibit transactions involving bio-derived compounds, biomanufacturing equipment, and automated scientific discovery tools.
• Brain-computer interfaces and bioinformatics tools are explicitly subject to the investment prohibition.
• Cash-based licensing deals without equity investment, such as those by Eli Lilly and Pfizer, are exempt from the new restrictions.
• The proposal follows the passage of the Comprehensive Outbound Investment National Security Act in 2025 and comes one month after the US-China trade truce extension.

Background

This development follows earlier reports of the Treasury preparing to tighten scrutiny on Chinese biotech acquisitions. In September 2026, US cancer patients began seeking Chinese drugs due to FDA delays, highlighting the complex interplay between regulatory speed and security concerns. The current proposal builds on previous drafts that distinguished between standard licensing and sensitive technologies, reflecting a shift toward rigorous oversight of cross-border pharmaceutical deals amid heightened geopolitical tensions.

How outlets are covering it

Politico highlights the conflict between the Treasury and PhRMA, the major drugmaker lobbying group, which argues that limits on investment will not slow Beijing’s biotech sector and may hinder access to cutting-edge treatments for American patients. The Financial Times emphasizes the national security rationale, noting that the rules target technologies with dual civilian and military uses, such as brain-computer interfaces, which pose acute risks for biological weapons proliferation. Endpoints News notes that the draft regulations would sharply limit US investments in much of China’s biotech sector, though the full details are behind a paywall. Craig Singleton of the Foundation for Defense of Democracies describes the biotech regulations as the most significant element of the package, warning that money flowing into China’s biotech sector carries national security consequences.

Why it matters

These proposed regulations could reshape the landscape of US-China biotech collaboration, potentially limiting access to innovative therapies while aiming to protect national security. The distinction between equity investments and cash-based licensing deals may influence how US pharmaceutical companies structure future partnerships with Chinese firms, balancing the need for innovation against geopolitical risks.

What to watch

The proposed regulations will be finalized after a period of public comment. Industry groups, including the Biotechnology Innovation Organization, are expected to continue lobbying against overly broad approaches that could create uncertainty for innovators and investors. The outcome of this process will determine the extent to which US capital can flow into sensitive Chinese technologies, with potential implications for both national security and the global pharmaceutical market.